Advancing CML Management Towards an Ideal Patient Journey

Opinion
Video

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following:

  • What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
  • What excites you most about the potential advancements in CML management that may be on the horizon in the next 5 to 10 years?
  • How do you envision the CML patient experience being transformed compared to today? What would an "ideal" CML journey look like for patients and their loved ones? What would be your top recommendations if you were to advise the broader healthcare system on how to better support CML patients and caregivers?
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.